Of note, consistent with changes in the proliferative and profibrogenic capacity, treatment with ANA in both LX-2 and HSC-T6 cells suppressed TGF-β1-mediated phosphorylation of ERK1/2 and Smad 2/3 (Figure 5DMcKenzie, C.A.; Tirona, R.G.; Summers, K.; Seney, S.; Chakrabarti, S.; Malhotra, N.; Beaton, M.D. Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial. This evidence concerns the gene MAPK3 and metabolic dysfunction-associated steatohepatitis.